Evista for prevention of breast cancer

Evista for prevention of breast cancer

Evista has advantages for women in the group of increased risk during menopause. Results of a large-scale, national study have shown that Evista is equivalent to other well-recognized breast cancer preventive remedy tamoxifen.

Moreover, Evista turned out to have fewer side effects in regard of uterine cancer and clotting problems, compared with women who take tamoxifen.

These results were showed by the study STAR (Study of Tamoxifen and Raloxifene), which involved more than 20 000 women in the menopause period.
The STAR participants agreed to take 20 milligrams of tamoxifen or 60 milligrams of Evista daily for five years.

Within four years, women in the group receiving tamoxifen had registered 163 cases of invasive breast cancer, compared with 167 in the group taking Evista.

"We see that compared with placebo, there is a 50% reduction in the risk of invasive breast cancer," says D. Lawrence Wickerham, STAR analyst and project specialist of National Surgical Adjuvent Breast and Bowel Project (NSABP). "Thus, we interpret these data to disclose such information: Evista, like tamoxifen, can reduce the risk of invasive breast cancer. We think that it gives women a real choice, as every year 150 000 women in the United States are diagnosed with breast cancer."

Evista Side effects

Cervical cancer and coagulation problems were reported much less frequently in women who used Evista than in the use of tamoxifen. Pulmonary embolism and deep vein thrombosis were significantly less with Evista, the researchers report. Cataract and cataract surgery were also less common with Evista as the study shows.

The only drawback of using Evista is a higher level of the non-invasive breast cancer among the STAR participants. In order to definitively determine the best option for breast cancer prevention, more time and additional researches are needed.

FDA has not approved yet the usage of Evista for the breast cancer prevention. The reason is that the FDA won't be able to protect the patients from counterfeits stating that anyway no one medicine can guarantee 100% cancer prevention.

Feb 23, 2014